Acquired ATM loss may be exploited for clinical benefit as pharmacologic ATR kinase inhibitors including VE-821, VE-822/VX970 and AZD6738 synergize with cisplatin to kill ATM-deficient cancer cells in vitro and to resolve xenograft models of ATM-deficient lung cancer in vivo [16–19]. This evidence concerns the gene ATM and lung cancer.